INSULIN 1
Australia ’ s only once-weekly GLP-1 RA indicated to reduce the risk of MAJOR ADVERSE CARDIOVASCULAR EVENTS
in adults with T2D at CV risk * 2 , 3
* As an adjunct to standard of care therapy 2
Consider offering your T2D patients a GLP-1 RA that combines :
Powerful HbA1c efficacy † 2 , 4-12
†
Trulicity demonstrated significant HbA1c reductions of -1.08 % to -1.64 % in people with T2D . 2 , 4-12
ठ2 , 13 , 14
Primary and secondary prevention of MACE
‡
Trulicity is indicated as an adjunct to standard of care therapy to reduce the risk of MACE in adults with T2D who have established CV disease or multiple CV risk factors . 2
§
MACE : composite of CV death , non-fatal MI or non-fatal stroke . 2 , 13
Simple delivery^2 , 15 , 16
^Once weekly dosing with a ready-to-use pen that 99 % of injection naïve patients found easy to use .
2 , 15 , 16
Titration is not required .
To find out more , contact Lilly on 1800 454 559 .
PBS Information : Authority Required ( STREAMLINED ). Type 2 diabetes . Criteria Apply . Refer to PBS Schedule for full Authority Required Information .
PLEASE REFER TO THE FULL PRODUCT INFORMATION BEFORE PRESCRIBING . FULL PRODUCT INFORMATION CAN BE ACCESSED AT WWW . LILLY . COM . AU / EN / PRODUCTS OR ON REQUEST BY CALLING 1800 454 559 .
TRULICITY ( dulaglutide rch ). INDICATIONS – TRULICITY is indicated for adult patients with Type 2 diabetes as 1 ) an adjunct to diet and exercise to improve glycaemic control ; and 2 ) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease . CONTRAINDICATIONS – Hypersensitivity to dulaglutide or any of the excipients . PRECAUTIONS – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis ; severe gastrointestinal disease – not recommended ; acute pancreatitis – discontinue treatment if suspected ; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk ; congestive heart failure – limited therapeutic experience . Use in Pregnancy Category B3 . ADVERSE EFFECTS Clinical Trials Experience – Very Common ( ≥10 %) gastrointestinal disorders ( nausea , vomiting and diarrhoea ), hypoglycaemia ( in combination with insulin non- / secretagogues and / or insulin ); Common ( ≥1 and < 10 %) abdominal pain , decreased appetite , dyspepsia , fatigue , hypoglycaemia ( as monotherapy ), immunogenicity , atrial fibrillation . DOSAGE AND ADMINISTRATION – Dosage : Adults ( ≥ 18 years ): 1.5 mg once weekly , at any time of day , independently of meals . Elderly Patients ( ≥65 years ): dose adjustment not required . Children and adolescents (< 18 years ): safety and effectiveness have not been established . Renal Impairment : no dose adjustment is required in mild , moderate or severe renal impairment ; not recommended in end-stage renal disease . Hepatic Impairment : no dose adjustment required . Administration : subcutaneous injection in the abdomen , thigh or upper arm . Should not be administered intravenously or intramuscularly . Single-use in one patient only . Discard the pen once the injection is completed . Please review full PI before prescribing . Full PI is available on request from Eli Lilly . Eli Lilly Australia Pty Ltd , 112 Wharf Road , West Ryde NSW 2114 . Phone 1800 454 559 . Based on PI approved 14 July 2020 .
ABBREVIATIONS : CV , cardiovascular ; GLP-1 RA , Glucagon-like peptide-1 receptor agonist ; MACE , Major Adverse Cardiovascular Events ; MI , myocardial infarction ; PBS , Pharmaceutical Benefits Scheme ; T2D , type 2 diabetes .
REFERENCES : 1 . Pharmaceutical Benefits Scheme . Available at : www . pbs . gov . au . Last accessed July 2021 . 2 . Trulicity Approved Product Information , July 2020 . 3 . Therapeutic Goods Administration . Available at : https :// www . ebs . tga . gov . au . Last accessed July 2021 . 4 . Wysham C et al . Diabetes Care 2014 ; 37:2159 – 67 . 5 . Giorgino F et al . Diabetes Care 2015 ; 38:2241 – 9 . 6 . Nauck M et al . Diabetes Care 2014 ; 37:2149 – 58 . 7 . Blonde L et al . Lancet 2015 ; 385:2057 – 66 . 8 . Dungan KM et al . Lancet 2014 ; 384:1349 – 57 . 9 . Tuttle et al . Lancet Diabetes Endocrinol 2018 ; 6:605-17 . 10 . Pozzilli P et al . Diabetes Obes Metab . 2017 ; 19:1024 – 1031 . 11 . Ludvik B , et al . Lancet Diabetes Endocrinol . 2018 ; 6:370 – 81 . 12 . Weinstock RS et al . Diabetes Obes Metab . 2015 ; 17:849-58 . 13 . Gerstein HC et al . Lancet 2019 ; 394:121 – 30 . 14 . World Health Organization . Available at : https :// www . who . int / cardiovascular _ diseases / guidelines / PocketGL . ENGLISH . AFR-D-E . rev1 . pdf . Last accessed July 2021 . 15 . Matfin G et al . J Diabetes Sci Technol 2015 ; 9:1071 – 9 . 16 . Trulicity Instructions for Use . November 2018 .
Trulicity ® is a registered trademark of Eli Lilly and Company . Eli Lilly Australia Pty Ltd . 112 Wharf Road , West Ryde NSW 2114 , Australia ABN 39 000 233 992 . Medical information : 1800 454 559 . Date of preparation : July 2021 . PP-DG-AU-0644 . ELI4465 .